公开(公告)号：US20100221747A1

公开(公告)日：2010-09-02

申请号：US12097460

申请日：2006-12-14

Applicant: Hiromi Ito

Inventor： Hiromi Ito

IPC: G01N33/573 ,  C12M1/34

CPC classification number: G01N33/56911 ,  G01N2333/31 ,  G01N2800/44

Abstract: It is intended to provide an immunochromatographic detection device which detects PBP2′ specifically produced by a multidrug-resistant Staphylococcus bacterium by an immunochromatographic detection method sensitively, simply and rapidly and is capable of determining infection with a multidrug-resistant Staphylococcus, a diagnostic method using the detection device, and a diagnostic kit including the detection device. The invention is directed to the immunochromatographic detection device for detecting a multidrug-resistant Staphylococcus which includes a sample supply unit which supplies a sample solution which is assumed to contain a multidrug-resistant Staphylococcus or a solution which is assumed to contain PBP2′ released from a cell wall by a pretreatment of a sample onto a sheet-shaped solid-phase support, a labeling reagent unit which retains a labeling reagent in which an antibody specifically binding to PBP2′ is labeled spreadable on the solid-phase support, and a trapping reagent unit in which a trapping reagent capable of trapping a complex of PBP2′ and the labeling reagent by specifically binding to the complex is immobilized, and in which an amphoteric surfactant; an anionic surfactant and/or a nonionic surfactant is contained in the trapping reagent unit or in the solid-phase support upstream of the trapping reagent unit.

Abstract translation: 旨在提供一种免疫色谱检测装置，其通过免疫色谱检测方法敏感地，简单且快速地检测由多重耐药性葡萄球菌特异性产生的PBP2'，并且能够确定多药耐药性葡萄球菌的感染，该方法使用 检测装置和包括检测装置的诊断试剂盒。 本发明涉及用于检测多重耐药性葡萄球菌的免疫色谱检测装置，其包括提供假定含有多重耐药性葡萄球菌的样品溶液的样品供应单元或假定含有从药物释放的PBP2'的溶液 通过将样品预处理到片状固相载体上的标记试剂单元，保留特异性结合PBP2'的抗体的标记试剂的标记试剂单元标记为可在固相载体上展开的捕获试剂 其中固定有能够通过特异性结合复合物捕获PBP2'复合物和标记试剂的捕获剂的单元，其中两性表面活性剂; 在捕集试剂单元或捕获试剂单元上游的固相载体中含有阴离子表面活性剂和/或非离子表面活性剂。

公开(公告)号：US20100179179A1

公开(公告)日：2010-07-15

申请号：US12700106

申请日：2010-02-04

Applicant: Elisabeth Buchdunger ,  Doriano Fabbro

Inventor： Elisabeth Buchdunger ,  Doriano Fabbro

IPC: A61K31/506

CPC classification number: A61K31/553 ,  A61K31/502 ,  A61K31/506 ,  G01N2800/44

Abstract: The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT is administered.

Abstract translation: 本发明涉及以突变体形式的KIT为特征的KIT依赖性疾病的治疗，由此鉴定突变型KIT并施用适当的突变型KIT抑制剂。

公开(公告)号：US20100112549A1

公开(公告)日：2010-05-06

申请号：US12595580

申请日：2008-04-18

Applicant: Diego Rey ,  Carl Batt ,  Leonardo Maestri Texeira

Inventor： Diego Rey ,  Carl Batt ,  Leonardo Maestri Texeira

IPC: C12Q1/70 ,  C12N7/01

CPC classification number: G01N33/56911 ,  C12Q1/6897 ,  G01N2800/44

Abstract: Embodiments of the present invention relate to selective organism detection, and, more particularly to recombinant bacteriophages and the use of such recombinant bacteriophages to detect target bacteria and to detect specific nucleic acid sequences within said target bacteria thus allowing for the detection of phenotypic characteristics of said bacteria such as determining drug(s) to which such target bacteria are resistant. The present invention further relates to sample preparation apparatuses for preparing samples for detection and analysis using bacteriophage-based techniques, that are low in cost, easy to use, and do not require technical expertise or any additional laboratory infrastructure to perform.

Abstract translation: 本发明的实施方案涉及选择性生物体检测，更具体地涉及重组噬菌体，以及使用这种重组噬菌体来检测靶细菌并检测所述靶细菌内的特定核酸序列，从而允许检测所述靶细菌的表型特征 诸如测定这些靶细菌抵抗的药物的细菌。 本发明还涉及用于制备用于使用基于噬菌体的技术进行检测和分析的样品的样品制备装置，其成本低，易于使用，并且不需要技术专长或任何额外的实验室基础设施来执行。

公开(公告)号：US20090144841A1

公开(公告)日：2009-06-04

申请号：US11901238

申请日：2007-09-13

Applicant: Ulrich Brinkmann ,  Sven Hoffmeyer ,  Esther Mornhinweg

Inventor： Ulrich Brinkmann ,  Sven Hoffmeyer ,  Esther Mornhinweg

IPC: A01K67/027 ,  C07H21/00 ,  C12N15/74 ,  C12N5/10 ,  C12Q1/68 ,  A61K31/7088 ,  A61P35/00 ,  G01N33/567 ,  C12P21/00 ,  C12N15/02 ,  C07K16/18

CPC classification number: C12Q1/6883 ,  C07K14/47 ,  C12Q2600/106 ,  C12Q2600/156 ,  C12Q2600/158 ,  G01N33/6893 ,  G01N2333/705 ,  G01N2500/04 ,  G01N2800/44

Abstract: The present invention relates to a polymorphic MRP-1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells. Furthermore, methods of identifying a polymorphism, identifying and obtaining a pro-drug or drug or an inhibitor are also encompassed by the present invention. In addition, the invention relates to methods for producing of a pharmaceutical composition and to methods of diagnosing a disease. Further, the invention relates to a method of detection of the polynucleotide of the invention. Furthermore, comprised by the present invention are a diagnostic and a pharmaceutical composition. Even more, the invention relates to uses of the polynucleotides, genes, vectors, polypeptides or antibodies of the invention. Finally, the invention relates to a diagnostic kit.

Abstract translation: 本发明涉及多形性MRP-1多核苷酸。 此外，本发明涉及包含本发明的多核苷酸的基因或载体，并涉及用本发明的多核苷酸或基因进行遗传工程改造的宿主细胞。 此外，本发明涉及用于产生分子变体多肽或其片段的方法，用于产生能够表达分子变体多肽的细胞的方法及其由本发明的多核苷酸或基因编码的多肽或其片段，或可由 方法或由本发明方法生产的细胞。 此外，本发明涉及特异性结合本发明多肽的抗体。 此外，本发明涉及转基因非人动物。 本发明还涉及包含一种或多种上述多核苷酸，基因，载体，多肽，抗体或宿主细胞的固体支持物。 此外，鉴定多态性，鉴定和获得前药或药物或抑制剂的方法也包括在本发明中。 此外，本发明涉及制备药物组合物的方法和诊断疾病的方法。 此外，本发明涉及本发明的多核苷酸的检测方法。 此外，本发明包括诊断和药物组合物。 更进一步地，本发明涉及本发明的多核苷酸，基因，载体，多肽或抗体的用途。 最后，本发明涉及诊断试剂盒。

公开(公告)号：US20090142796A1

公开(公告)日：2009-06-04

申请号：US11950388

申请日：2007-12-04

Applicant: Charles Yu ,  Curtis Michael Gosnell ,  Vicki Whitley ,  David J. Turner

Inventor： Charles Yu ,  Curtis Michael Gosnell ,  Vicki Whitley ,  David J. Turner

IPC: C12Q1/18 ,  C12M1/22

CPC classification number: C12Q1/04 ,  C12Q1/18 ,  G01N33/6893 ,  G01N2800/44

Abstract: The embodiments of this invention provide a test panel and method for the detection of inducible resistance to macrolide-lincosamide-streptogramin b (iMLSb) in microorganisms in an automated microorganism identification (ID) and antimicrobial susceptibility determinations (AST) system.The wells of a multiple-well test panel contain a macrolide agent and a lincosamide agent and a combination of both macrolide agent and lincosamide agent. The test panel is inoculated with a broth-suspended microorganism, and placed into the automated microorganism identification (ID) and antimicrobial susceptibility determinations (AST) system. The test panel is incubated within the system and the wells monitored for microorganism growth.

Abstract translation: 本发明的实施方案提供了用于在自动化微生物鉴定（ID）和抗微生物敏感性测定（AST）系统中检测微生物中大环内酯 - 林必酰胺 - 链霉素b（iMLSb）的诱导型抗性的测试板和方法。 多孔测试板的孔含有大环内酯类药剂和林可酰胺试剂以及大环内酯类药剂和林可素剂的组合。 测试面板用培养液悬浮的微生物接种，并置于自动化微生物鉴定（ID）和抗微生物敏感性测定（AST）系统中。 将测试面板在系统内温育并监测微生物生长。

公开(公告)号：US20090124539A1

公开(公告)日：2009-05-14

申请号：US12284954

申请日：2008-09-26

Applicant: Ake P. Elhammer ,  Torsten Stachelhaus

Inventor： Ake P. Elhammer ,  Torsten Stachelhaus

IPC: A61K38/12 ,  C07H21/00 ,  C07K14/00 ,  A61P31/04

CPC classification number: G01N33/56916 ,  A61K38/15 ,  G01N33/56938 ,  G01N33/56944 ,  G01N2800/44

Abstract: The present invention relates to methods of inhibiting the proliferation of bacteria for either ex vivo or in vivo use. The invention also relates to methods of treating a patient infected with an antibiotic resistant bacteria by administering a pharmaceutical composition comprising an Empedopeptin; methods of sanitizing surfaces and instruments; and methods of assaying bacteria for Empedopeptin resistance.

Abstract translation: 本发明涉及抑制细菌增殖的方法，用于离体或体内使用。 本发明还涉及通过施用包含刺激肽的药物组合物来治疗感染抗生素抗性细菌的患者的方法; 消毒表面和仪器的方法; 以及用于测定细菌的Empeptpeptin抗性的方法。

公开(公告)号：US20080206781A1

公开(公告)日：2008-08-28

申请号：US11678209

申请日：2007-02-23

Applicant: Donald W. Miller ,  Corbin J. Bachmeier ,  Richard B. Lomneth

Inventor： Donald W. Miller ,  Corbin J. Bachmeier ,  Richard B. Lomneth

IPC: G01N33/53

CPC classification number: G01N33/542 ,  G01N2500/10 ,  G01N2800/44

Abstract: The present invention relates to high-throughput cell-based assays for real-time monitoring of multi-resistant drug protein activity. The present invention is an improvement over existing assays in that in addition to a fluorescent drug efflux probe as an indicator of MDR protein activity, the instant assays provide an o-tolidine-based dye for quenching extracellular fluorescence of the probe.

Abstract translation: 本发明涉及用于实时监测多重耐药性蛋白质活性的高通量的基于细胞的测定法。 本发明是对现有测定的改进，因为除了作为MDR蛋白活性的指示剂的荧光药物外排探针之外，本发明提供了一种用于猝灭探针的细胞外荧光的邻甲苯胺染料。

公开(公告)号：US07358042B2

公开(公告)日：2008-04-15

申请号：US10801988

申请日：2004-03-15

Applicant: Elias Georges ,  Lucile Serfass ,  Anne-Marie Bonneau ,  Frédéric Dallaire

Inventor： Elias Georges ,  Lucile Serfass ,  Anne-Marie Bonneau ,  Frédéric Dallaire

IPC: C12Q1/00 ,  G01N33/53 ,  A61K39/395 ,  C07K16/30

CPC classification number: G01N33/57496 ,  G01N33/5017 ,  G01N2333/99 ,  G01N2800/44 ,  G01N2800/52

Abstract: Disclosed are methods for detecting neoplastic or damaged cells and for detecting multidrug resistance in neoplastic or damaged cells by detecting an increase in the cellular expression of a triosephosphate isomerase (TPI) protein in a multidrug resistant neoplastic or damaged cells as compared to the level of expression of the triosephosphate isomerase protein in a normal cell.

Abstract translation: 公开了通过检测多药耐药肿瘤或损伤的细胞中的磷酸三磷酸异构酶（TPI）蛋白的细胞表达的增加而与肿瘤或受损细胞的表达水平相比，检测肿瘤或损伤的细胞和检测肿瘤或受损细胞的多药耐药性的方法 的三磷酸异构酶蛋白。

公开(公告)号：US20070254319A1

公开(公告)日：2007-11-01

申请号：US11733114

申请日：2007-04-09

Applicant: Vera Donnenberg ,  Albert Donnenberg

Inventor： Vera Donnenberg ,  Albert Donnenberg

IPC: G01N33/574 ,  C12N5/08

CPC classification number: C12N5/0695 ,  C12N5/0093 ,  G01N33/5011 ,  G01N33/5073 ,  G01N2500/10 ,  G01N2800/44

Abstract: In one embodiment, the invention provides a method of identifying and isolating a cancer MDR stem cell. In another embodiment, the invention provides an isolated cancer MDR stem cell and a population of such cells. In yet another embodiment, the invention provides a method of screening a test compound for its ability to kill or impede proliferation of MDR cancer stem cells.

Abstract translation: 在一个实施方案中，本发明提供了鉴定和分离癌症MDR干细胞的方法。 在另一个实施方案中，本发明提供了分离的癌症MDR干细胞和这种细胞群体。 在另一个实施方案中，本发明提供了筛选受试化合物以杀死或阻碍MDR癌症干细胞增殖的能力的方法。

公开(公告)号：US20070213317A1

公开(公告)日：2007-09-13

申请号：US10579586

申请日：2004-11-17

Applicant: Elisabeth Buchdunger ,  Doriano Fabbro

Inventor： Elisabeth Buchdunger ,  Doriano Fabbro

IPC: A61K31/506 ,  A61K31/553

CPC classification number: A61K31/553 ,  A61K31/502 ,  A61K31/506 ,  G01N2800/44

Abstract: The present invention relates to the treatment of KIT dependent diseases that are characterized by a mutant form of KIT whereby the mutant KIT is identified and an appropriate inhibitor of the mutant KIT selected form midostaurin, vatalanib and compound A is administered.

Abstract translation: 本发明涉及KIT依赖性疾病的治疗，其特征在于突变体形式的KIT，由此鉴定突变型KIT，并且施用选自Midostaurin，瓦他拉尼和化合物A的突变型KIT的合适的抑制剂。